RCS - Diaceutics PLC - "Precision Medicine in Oncology " Virtual Event

DiaceuticsAnnouncement

13/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240613:nRSM2239Sa&default-theme=true

RNS Number : 2239S  Diaceutics PLC  13 June 2024

Diaceutics and Labroots Announce "Precision Medicine in Oncology " Virtual
Event:

 

A Cutting-Edge Exploration of Cancer Diagnostics & Treatment

 

Belfast and London, 13 June 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and biotech industry, is
pleased to announce its upcoming virtual event to be hosted in collaboration
with Labroots - "Precision medicine in oncology
(https://www.labroots.com/ms/virtual-event/precision-medicine-oncology/flagship)
," on 19 June, 2024.

 

This groundbreaking event will take attendees to the forefront of cancer
testing & treatment through a series of eight live webinars, culminating
in a full day of immersive, true-to-life virtual experiences. The virtual
sessions will cover topics that are revolutionising cancer analysis &
diagnostics, including immunotherapy; liquid biopsy; pre-analytical phase;
NGS; Cytology and CE marked Invitro-Diagnostic Regulations.

 

Event Speakers will include:

 

 ·         Prof. Dr. Klaus Pantel, Director of the Institute of Tumor Biology at the
           University Medical Center Hamburg-Eppendorf, Germany: Presenting
           "Implementation of Liquid Biopsy in Precision Oncology," Prof. Pantel, a
           pioneer in cancer cell research, will provide a comprehensive introduction to
           and review of the evolution of precision medicine, focusing on the
           implementation of liquid biopsy in precision oncology.
 ·         Dr. Bob Holt, Senior Precision Medicine Strategy Advisor at Diaceutics:
           Presenting "MRD in Solid Tumor and Hematological Indications: Today and
           Tomorrow," Dr. Holt will analyse the clinical utility and technology behind
           Minimal Residual Disease (MRD). This session will be followed by Prof. Maria
           Teresa Voso, Prof. of Hematology at Tor Vergata University, who will discuss
           the pros and cons of MRD in AML and engage in a discussion with Dr. Holt and
           all attendees.
 ·         Prof. Paul Hoffman, Professor of Pathology at the University Côte d'Azur,
           Nice, France: Presenting on "New challenges in early-stage cancer". This
           presentation will explore early detection and management of early-stage
           cancers.
 ·         Dr. Clare Turnbull, PhD FRCP FRCPath FFPH, Professor of Translational Cancer
           Genetics in the Division of Genetics & Epidemiology at the Institute of
           Cancer Research and NHS Honorary Consultant in Clinical Cancer Genetics,
           London and Dr Nicola Normanno, MD, Director of Translational Research,
           National Cancer Institute, Pascale Foundation, Italy: Presenting "The Role of
           Comprehensive Genomic Profiling in Precision Oncology," this session promises
           insights into the implications of large NGS panels, co-mutations, and the
           introduction of patients harboring germline variants.
 ·         Prof. Sophie Prévot, Pathologist at the Bicêtre Hospital, Paris: Presenting
           "Integrating AI in Pathology: Advancing Diagnoses & Workflow Efficiency,"
           this presentation will explore how AI tools can support doctors in making
           accurate diagnoses and enhancing workflow efficiency.

 

Ryan Keeling, CEO of Diaceutics, commented, "Our commitment is to transform
the landscape of cancer treatment through precision medicine. This event
provides an unparalleled platform for experts to share innovative practices
and insights that will shape the future of oncology diagnostics. We are
pleased to host this gathering of thought leaders and advance our mission of
ensuring every patient receives the right treatment at the right time."

 

The event is tailored for laboratory professionals, pathologists, and anyone
involved in oncology diagnostics and treatment. In addition to the expert
presentations, attendees can participate in interactive sessions, visit the
poster hall, and engage in real-time Q&A sessions with expert speakers.

 

For further information about the event and to register for free, click here
(https://www.labroots.com/ms/virtual-event/precision-medicine-oncology) .

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network®.

 

About Labroots

Labroots (https://www.labroots.com/) is the leading scientific social
networking website, and primary source for scientific trending news and
premier educational virtual events and webinars and more. Contributing to the
advancement of science through content sharing capabilities, Labroots is a
powerful advocate in amplifying global networks and communities. Founded in
2008, Labroots emphasises digital innovation in scientific collaboration and
learning. Offering more than articles and webcasts that go beyond the mundane
and explore the latest discoveries in the world of science, Labroots users can
stay atop their field by gaining continuing education credits from a wide
range of topics through their participation in the webinars and virtual
events.

 

Enquiries:

 Diaceutics PLC
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com

 Kinvara Verdon

 Kieran Breheny

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUUAWRSAUNAAR